PROVEN EFFICACY INSCALP PSORIASIS1*

Sustained improvement inscalp psoriasisup to 1 year1,a,b

aESTEEM 2 study. Data as observed; includes patients who were randomized to OTEZLA 30 mg BID or placebo at baseline, were PASI-50 responders at week 32, and who continued to receive OTEZLA 30 mg BID up to week 52.

OTEZLA SUSTAINSIMPROVEMENT INSCALP PSORIASIS2,3

Significant and sustained improvement in scalp psoriasis2,3,a

aLIBERATE study. mITT, LOCF. Includes patients with ScPGA ≥3 (moderate or greater) at baseline. Response at week 16 and week 104 was determined using the LOCF methodology. Week 104 analysis includes patients who entered the apremilast extension phase and were treated in the phase.

Psoriatic Arthritis

Disclaimer: This is an international website for OTEZLA® (apremilast). The information on this site is not country-specific. It may contain information that is outside the approved indications in the country in which you are located. If you are a US resident, please click on the US residents link at the top of this page.